Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

NEXT STORY
PM360 8th Annual ELITE Awards Open for Submissions
PREV STORY
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split

Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ...

author_avatar
NASDAQ Market News

Relievant Appoints Christopher Geyen Chief Financial Officer

SUNNYVALE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Relievant Medsystems, a privately held medical ...

author_avatar
NASDAQ Market News

Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News